David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Comcast
CMCSA
|
+$354M |
| 2 |
Wells Fargo
WFC
|
+$274M |
| 3 |
IBM
IBM
|
+$266M |
| 4 |
Qualcomm
QCOM
|
+$257M |
| 5 |
Mondelez International
MDLZ
|
+$224M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$356M |
| 2 |
PayPal
PYPL
|
+$290M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$261M |
| 4 |
NVIDIA
NVDA
|
+$248M |
| 5 |
AABA
Altaba Inc
AABA
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.31% |
| 2 | Healthcare | 10.66% |
| 3 | Consumer Discretionary | 10.29% |
| 4 | Communication Services | 8.78% |
| 5 | Financials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2226
PUT
Broadcom
AVGO
$1.7T
| $1.43M | ﹤0.01% |
59,000
-205,000
| -78% | -$5.07M |
|
2227
Coherus Oncology
CHRS
$212M
| $1.43M | ﹤0.01% |
107,021
-12,279
| -10% | -$162K |
|
2228
APA Corp
APA
$14.5B
| $1.43M | ﹤0.01% |
31,143
+8,559
| +38% | +$377K |
|
2229
Freshpet
FRPT
$3.62B
| $1.43M | ﹤0.01% |
91,098
-39,486
| -30% | -$636K |
|
2230
SM Energy
SM
$8.49B
| $1.42M | ﹤0.01% |
80,204
-80,079
| -50% | -$1.25M |
|
|
BKI
2231
DELISTED
Black Knight, Inc. Common Stock
BKI
| $1.42M | ﹤0.01% |
33,035
+21,656
| +190% | +$919K |
|
|
UPL
2232
DELISTED
Ultra Petroleum Corp. Common Stock
UPL
| $1.42M | ﹤0.01% |
164,045
+126,347
| +335% | +$1.15M |
|
2233
Helix Energy Solutions
HLX
$1.47B
| $1.41M | ﹤0.01% |
191,147
-23,190
| -11% | -$147K |
|
2234
HealthStream
HSTM
$844M
| $1.41M | ﹤0.01% |
60,407
-6,916
| -10% | -$164K |
|
|
UBNK
2235
DELISTED
United Financial Bancorp, Inc.
UBNK
| $1.41M | ﹤0.01% |
76,932
-4,488
| -6% | -$78K |
|
2236
AMC Entertainment Holdings
AMC
$2.37B
| $1.41M | ﹤0.01% |
9,556
+7,748
| +429% | +$1.29M |
|
2237
A.O. Smith
AOS
$8.45B
| $1.4M | ﹤0.01% |
+23,532
| New | +$1.32M |
|
2238
MasterCraft Boat Holdings
MCFT
$599M
| $1.4M | ﹤0.01% |
68,575
+20,338
| +42% | +$378K |
|
2239
New Jersey Resources
NJR
$5.46B
| $1.4M | ﹤0.01% |
+33,146
| New | +$1.4M |
|
2240
TFS Financial
TFSL
$4.99B
| $1.39M | ﹤0.01% |
86,368
+14,941
| +21% | +$231K |
|
2241
Harmony Gold Mining
HMY
$14.3B
| $1.39M | ﹤0.01% |
759,876
-772,929
| -50% | -$1.42M |
|
2242
Artisan Partners
APAM
$3.1B
| $1.39M | ﹤0.01% |
42,542
-10,465
| -20% | -$325K |
|
2243
Fossil Group
FOSL
$323M
| $1.39M | ﹤0.01% |
148,684
-263,408
| -64% | -$2.47M |
|
2244
PUT
Sarepta Therapeutics
SRPT
$2B
| $1.38M | ﹤0.01% |
30,500
-200
| -0.7% | -$7.99K |
|
|
WBT
2245
DELISTED
Welbilt, Inc.
WBT
| $1.38M | ﹤0.01% |
+60,012
| New | +$1.21M |
|
|
BID
2246
CALL
DELISTED
Sotheby's
BID
| $1.38M | ﹤0.01% |
30,000
| – | – |
|
|
KEM
2247
PUT
DELISTED
KEMET Corporation
KEM
| $1.37M | ﹤0.01% |
+65,000
| New | +$1.23M |
|
2248
PUT
Crown Castle
CCI
$32.5B
| $1.37M | ﹤0.01% |
+13,700
| New | +$1.4M |
|
|
UMH
2249
UMH Properties
UMH
$1.41B
| $1.37M | ﹤0.01% |
88,048
+41,649
| +90% | +$667K |
|
2250
PUT
Albemarle
ALB
$15.7B
| $1.36M | ﹤0.01% |
10,000
| – | – |
|
Similar funds
David Shaw's Q3 2017 Portfolio in Review
As of Q3 2017, David Shaw held 3,794 positions worth $65.1B, up 7.7% from $60.5B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.
David Shaw's Q3 2017 filing shows 469 new, 1,367 increased, 1,237 reduced and 370 closed positions. Its largest new stake was Baker Hughes: 3,076,914 shares worth $113M. The largest sale was Gilead Sciences, an estimated $356M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- David Shaw's largest Q3 2017 buy was Baker Hughes: 3,076,914 shares worth $113M.
- David Shaw added most to Comcast in Q3 2017, an estimated $354M increase.
- David Shaw's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $356M.
- David Shaw fully exited Mobileye N.V. in Q3 2017, selling an estimated $72.4M.
- David Shaw's ten largest holdings make up 9.6% of its $65.1B portfolio in Q3 2017.
- David Shaw opened 469 new positions and closed 370 in Q3 2017.
- David Shaw's portfolio value rose 7.7% quarter-over-quarter to $65.1B.
Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.